ABVC BioPharma, Inc. (ECOC)

Every figure this model derived for ECOC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2023-12-31
cash 94,364 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 411,729 AssetsCurrent 2026-06-30
current liabilities 5,694,505 LiabilitiesCurrent 2026-06-30
equity 10,287,183 StockholdersEquity 2026-06-30
interest expense 155,210 InterestExpenseNonoperating 2026-06-30
ocf -2,690,948 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 296,000 RevenueFromContractWithCustomerIncludingAssessedTax 2025-12-31
sbc 3,562,845 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ECOC on one particular measure came for.

RatioValue
cash operating margin-987.41
current ratio0.07
current ratio reported0.07
deferred revenue growth-84.47
dilution pct72.32
fcf margin-909.1
growth cv2.51
interest cover-41.98
operating margin-2201.1
roic-50.5
sbc pct revenue1203.66

What to be careful about

What this model itself distrusts about ECOC's figures. Written by the derivation as it ran, not added afterwards.